Last reviewed · How we verify
Omega-3 treatment
Omega-3 fatty acids reduce inflammation and modulate lipid metabolism to improve cardiovascular and metabolic outcomes.
Omega-3 fatty acids reduce inflammation and modulate lipid metabolism to improve cardiovascular and metabolic outcomes. Used for Hypertriglyceridemia, Secondary prevention of cardiovascular disease, Reduction of cardiovascular events in high-risk patients.
At a glance
| Generic name | Omega-3 treatment |
|---|---|
| Also known as | Dietary intervention |
| Sponsor | University Hospital, Toulouse |
| Drug class | Lipid-modifying agent / Anti-inflammatory |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Omega-3 polyunsaturated fatty acids (EPA and DHA) decrease triglyceride levels, reduce platelet aggregation, and lower inflammatory markers including C-reactive protein and cytokines. They also improve endothelial function and may stabilize atherosclerotic plaques, reducing cardiovascular events in at-risk populations.
Approved indications
- Hypertriglyceridemia
- Secondary prevention of cardiovascular disease
- Reduction of cardiovascular events in high-risk patients
Common side effects
- Gastrointestinal upset (nausea, dyspepsia, diarrhea)
- Fishy aftertaste or odor
- Bleeding or bruising (at high doses)
- Headache
Key clinical trials
- Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction (PHASE2)
- NMDA Enhancement Combined With Omega-3 for Early Dementia (PHASE2)
- A Clinical Trial Via Telepsychiatry of Treatments for the Management of Emotional Dysregulation in Youth (PHASE4)
- Pharmacokinetic Study of Eicosapentaenoic Acid (EPA) and Calcium L-5-Methyltetrahydrofolate (L-5-MTHF) After Administration of CreNeuroS® CNS Fish Oil Plus Softgels in Healthy Subjects Under Fasting Conditions (NA)
- OMEGA - Dietary Intervention - COPD Trial (NA)
- Preoperative Fish Oil PN and Prognosis After Constipation Surgery
- n-3 Polyunsaturated Fatty Acids to Prevent and Treat Diabetic Neuropathy (NA)
- NUTRIBRAIN: Lifestyle Interventions to Prevent cOgnitive Deficits in Subjects With Depressive Symptoms: From mEchanisms to Clinical pRactice (POWER) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omega-3 treatment CI brief — competitive landscape report
- Omega-3 treatment updates RSS · CI watch RSS
- University Hospital, Toulouse portfolio CI